Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis

NCT00646035 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00646035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00646035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective, Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2002
Completion date
Not reported
Enrollment
75 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease